Browse by Poster Presenter

Skip to main content

ACoP 2024 Main banner

Conference Program

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

S
Sachs, Jeffrey

Quantitative Pharmacology and PMX, Merck & Co., Inc., USA
(W-106) Comparing Predicted Serotype-specific Vaccine Effectiveness of Pneumococcal Conjugate Vaccines V114 and PCV20 in Children using a novel model-based meta-analysis approach
Jeffrey Sachs
Favorite
Sale, Mark

Integrated Drug Development, Certara Inc.
(M-097) Automatic differentiation, a possible solution to numerical instability in Population PK parameter estimation
Mark Sale
Favorite
Salian, Vrishali

Department of Pharmaceutics, University of Minnesota-Twin Cities
(T-105) Generating data-driven insights from the Alzheimer’s Disease Neuroimaging Initiative (ADNI): Towards establishing a QSP model of Alzheimer’s disease
Vrishali Salian
Favorite
Salimgareev, Ruslan

Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University
(W-107) Mechanistic Modeling Of Surface Molecule Interactions: Impact Of Methodology On CAR-T Cell Dose Predictions
Ruslan Salimgareev
Favorite
Salinger, David

Certara, Inc.
(M-098) Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK of participants with Mycobacterium tuberculosis
David Salinger
Favorite
Sandefur, Conner

Simulations Plus Inc
(T-106) Simulated CD8+ T Cell-Mediated Liver Injury During Ipilimumab Administration in a Simulated Population (SimPops®) Demonstrates Profiles Consistent with Observed Clinical Data
Conner Sandefur
Favorite
Saqr, Abdelrahman

University of Minnesota
(W-108) Incorporating High Dimensional Gut Microbiome Data into Population Pharmacokinetic Modeling of Mycophenolate Mofetil
Abdelrahman Saqr
Favorite
Sayama, Hiroyuki

Nonclinical Biomedical Science, Astellas Pharma Inc.
(T-107) Comprehensive Human Quantitative Systems Pharmacology Models for Immuno-Oncology: Enhancing Decision-Making on Target Indications and Combination Strategies for New Drug Development
Hiroyuki Sayama
Favorite
Schaller, Stephan

ESQlabs GmbH
(T-050) A review of OSP suite PBBM capabilities: looking ahead
Stephan Schaller
Favorite
Scheuher, Bruna

Takeda
(T-088) A Computational Modeling Framework to Provide a Feasibility Assessment, Inform Competitor Differentiation Strategy, Best-in-Class Properties, and Target Selection for Biologics Targeting IBD
Bruna Scheuher
Favorite
Schiavone, Carmine

University of Naples "Federico II"
(T-035) Identifying Determinants of Vaccine Efficacy: A Mechanistic Modeling Approach
Carmine Schiavone
Favorite
Shahinuzzaman, Md

AstraZeneca
(W-109) Comparative Analysis of Minimal Physiologically Based Pharmacokinetic (mPBPK) and Traditional Pharmacokinetic (PK) Models in the Context of Quantitative Systems Pharmacology (QSP) for T-cell Engagers
Md Shahinuzzaman
Favorite
SHAH, ZEEL

Bristol Myers Squibb
(M-099) Advancing Drug Development in Relapsed and Refractory Multiple Myeloma (RRMM): Assessing the Safety and Efficacy Landscape Utilizing Model-Based Meta-Analysis
ZEEL SHAH
Favorite
Shaik, Jafar Sadik

Johnson & Johnson
(W-110) PK/PD Modeling of the Anti-FcRn Monoclonal Antibody Nipocalimab Administered to Healthy Subjects and Participants with Moderate to Severe Active Rheumatoid Arthritis
Jafar Sadik Shaik
Favorite
SHAO, SHUAI

Sanofi
(T-108) Comparison of NONMEM and AI-Based Approaches for Population Pharmacokinetic Simulations to Support Model-Informed Drug Development
SHUAI SHAO
Favorite
(T-109) Model-Based Analysis of Pharmacokinetics of Venglustat, a small-molecule inhibitor of glucosylceramide synthase, Using Pooled Data from Healthy Subjects and Patients with Lysosomal Storage Disorders
SHUAI SHAO
Favorite
Shapiro, Monica

Pfizer
(M-100) A Quantitative Systems Pharmacology Model of LNP-mRNA Uptake Through LDLR Binding
Monica Shapiro
Favorite
Sheehan, Robert

Rosa & Co. LLC
(W-034) Parallel Tempering for Generation of Virtual Patients and Virtual Populations
Robert Sheehan
Favorite
Shelly, Iris

NTT Research, Inc.
(M-101) Cardiovascular Model Parameterization of Digital Twins for Acute Care Drug Delivery: An Iterative Bayesian Approach
Iris Shelly
Favorite
Shenkoya, Babajide

University of Maryland Baltimore
(W-111) Pharmacokinetics of Long-Acting Naltrexone in Pregnancy: Insights from Physiologically Based Pharmacokinetic Modeling
Babajide Shenkoya
Favorite
Shi, Jian

BMS
(W-112) Use of Model-Informed Drug Development (MIDD) to Support Dose Selection of Nivolumab in Combination with Ipilimumab in Adolescent Patients with MSI-H/dMMR Metastatic Colorectal Cancer
Jian Shi
Favorite
(W-113) Population Pharmacokinetic and Exposure-Response Analyses of Nivolumab in Combination with Ipilimumab to Support Dosing Regimen in Subjects with First-Line MSI-H/dMMR Metastatic Colorectal Cancer
Jian Shi
Favorite
Shin, Euibeom

University at Buffalo school of pharmacy and pharmaceutical science
(M-103) Evaluation of ChatGPT and Gemini large language models for pharmacometrics with NONMEM
Euibeom Shin
Favorite
(M-104) Evaluation of prompt engineering strategies for pharmacokinetic data analysis with the ChatGPT large language model
Euibeom Shin
Favorite
Shi, Yufei

Fudan University
(M-102) Population Pharmacokinetics and Exposure-Response Analysis of Birociclib Plus Fulvestrant in Advanced Breast Cancer Patients
Yufei Shi
Favorite
Shroff, Sanaya

Vertex Pharmaceuticals
(T-110) Simulation of Trial Predictions with Model Uncertainty using NMsim
Sanaya Shroff
Favorite
Siripuram, Vijay

Astellas Pharma
(W-114) Consideration of Study design aspects in the creation of virtual populations for organ impairment studies: One size may not fit all
Vijay Siripuram
Favorite
Skataric, Maja

Novartis
(W-137) Immune thrombocytopenia purpura (ITP) indication extension allowing for administration of Eltrombopag in adult patients who are refractory to 1L-treatment irrespective of time since diagnosis
Maja Skataric
Favorite
Soliman, Amira

Center for Pharmacometrics & Systems Pharmacology
(W-115) Leveraging PBPK modeling to advance spironolactone complex disposition knowledge
Amira Soliman
Favorite
Song, Eric

Genmab US, Inc.
(T-112) Application of Machine Learning Methods to Predict Risk of Adverse Events in Clinical Trials
Eric Song
Favorite
Sorribes, Inmaculada

Quantitative Pharmacology and Pharmacometrics Immune/Oncology (QP2-I/O), Merck & Co., Inc., Rahway, New Jersey, USA
(W-116) Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)
Inmaculada Sorribes
Favorite
Soufsaf, Sara

Syneos Health
(W-117) PMXModelStructuR: A Tool for Pharmacometrics Model Visualization in R
Sara Soufsaf
Favorite
Spinosa, Phillip

Genentech, Inc.
(T-113) QSP model trained on preclinical data informs clinical dose selection for a T-cell engaging bispecific antibody for solid tumor indications
Phillip Spinosa
Favorite
Stadt, Melissa

University of Waterloo
(M-105) Sex differences in patients with chronic kidney disease: A quantitative systems pharmacology modeling study
Melissa Stadt
Favorite
Stephens, Hunter

Certara
(M-106) A Model-Informed Drug Development Framework for the Development and Dose Optimization of Targeted Radiation Therapies
Hunter Stephens
Favorite
Sukumar, Prema

Bristol Myers Squibb
(T-114) SAS Macro for Validation of NONMEM Data Items Pertaining to Implicit Expansion of Dose Records in Oral Dose Population Pharmacokinetic Datasets
Prema Sukumar
Favorite
Sunkaraneni, Soujanya

Syndax Pharmceuticals, Inc., Walthman, MA
(W-119) Population pharmacokinetics of revumenib in patients with relapsed/refractory acute leukemias
Soujanya Sunkaraneni
Favorite
Sun, Kefeng

Takeda Development Center Americas Inc
(M-107) Physiologically-Based Pharmacokinetic Modeling of Maribavir Incorporating Metabolism by Cytochrome P450, Glucuronidation, and Hepatic Uptake, for Prediction of Victim Drug-Drug Interaction Potentials
Kefeng Sun
Favorite
Sun, Steven

UCSD
(W-118) Evaluation of the population pharmacokinetics of pexmetinib in a simultaneous model of two formulations
Steven Sun
Favorite